v3.23.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues $ 3,104 $ 2,649
Cost of Revenues 791 797
Gross Profit 2,313 1,852
Operating Expenses    
Research and development 1,983 2,124
Sales and marketing 1,115 1,169
General and administrative 5,613 7,334
Acquisition-related costs 164 115
Transaction costs 1,400 0
Amortization of intangibles 220 347
Total Operating Expenses 10,495 11,089
Loss from Operations (8,182) (9,237)
Other (Expense)/Income    
Interest (expense)/income, net (1,725) 1
Other income/(expense), net 29 (44)
Unrealized gain/(loss) on equity securities 34 (1,503)
Total Other Expense (1,662) (1,546)
Net Loss from Continuing Operations, before tax (9,844) (10,783)
Income tax provision (2,478) 0
Net Loss from Continuing Operations (12,322) (10,783)
Loss from Discontinued Operations, Net of Tax (4,856) (774)
Net Loss (17,178) (11,557)
Net Loss Attributable to Non-controlling Interest (305) (346)
Net Loss Attributable to Stockholders of Inpixon (16,873) (11,211)
Net Loss Attributable to Common Stockholders, Basic (16,873) (17,362)
Net Loss Attributable to Common Stockholders, Diluted $ (16,873) $ (17,362)
Net Income (Loss) Per Share    
Net Loss Per Share - Basic (in usd per share) $ (1.38) $ (9.05)
Net Loss Per Share - Diluted (in usd per share) $ (1.38) $ (9.05)
Weighted Average Shares Outstanding    
Basic (in shares) 12,238,684 1,917,629
Diluted (in shares) 12,238,684 1,917,629
Series 7 Convertible Preferred Stock    
Other (Expense)/Income    
Accretion of preferred stock $ 0 $ (4,555)
Series 8 Convertible Preferred Stock    
Other (Expense)/Income    
Accretion of preferred stock 0 (548)
Deemed dividend for the modification related to Series 8 Preferred Stock 0 (2,627)
Deemed contribution for the modification related to Warrants issued in connection with Series 8 Preferred Stock 0 1,469
Amortization premium- modification related to Series 8 Preferred Stock $ 0 $ 110

Source